Literature DB >> 21668348

Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit.

Roberta P A Manzano1, Gholam A Peyman, Petros E Carvounis, Francisco Max Damico, Renata Genaro Aguiar, Gabriela L Ioshimoto, Dora Fix Ventura, Sylvia T Cursino, Walter Takahashi.   

Abstract

PURPOSE: To evaluate the ocular toxicity of escalating doses of intravitreous adalimumab (Humira®) in the rabbit eye.
METHODS: Thirty New Zealand albino rabbits received intravitreous injections of 0.5 mg (6 eyes), 1.0 mg (6 eyes), 2.5 mg (6 eyes), 5 mg (6 eyes), and 10 mg (6 eyes) adalimumab. Slit lamp biomicroscopy and fundoscopy were carried out at baseline, day 7, and day 14 after intravitreous injection, whereas electroretinography (ERG) was carried out at baseline and day 14. Animals were euthanized on day 14, and histopathological examination of the eyes was performed.
RESULTS: Slit lamp biomicroscopy and fundoscopy were normal in all eyes receiving doses up to 5 mg. In the 10 mg group, 3 of 6 eyes showed mild anterior chamber inflammatory reaction on day 7. Similarly, scotopic and photopic a- and b-wave ERG amplitudes at baseline and day 14 were similar in all groups up to 5 mg, but there was a significant decrease in the photopic-wave ERG response in the 10 mg group (P=0.046). Finally, histopathology demonstrated no differences among eyes receiving balanced salt solution, 0.5, 1.0, 2.5, 5.0, or 10 mg of adalimumab.
CONCLUSIONS: Intravitreous adalimumab exhibited no associated ocular short-term toxicity in rabbit eyes up to the 5 mg dose. In the 10 mg group mild clinical findings and ERG amplitude reduction could reflect early toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668348     DOI: 10.1089/jop.2010.0174

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  7 in total

Review 1.  Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders.

Authors:  Isabel Pascual-Camps; Pablo Hernández-Martínez; Laura Monje-Fernández; Rosa Dolz-Marco; Roberto Gallego-Pinazo; Lihteh Wu; J Fernando Arévalo; Manuel Díaz-Llopis
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-10-15

Review 2.  A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.

Authors:  Nasiq Hasan; Rohan Chawla; Nawazish Shaikh; Sindhuja Kandasamy; Shorya Vardhan Azad; M Dheepak Sundar
Journal:  Ther Adv Ophthalmol       Date:  2022-05-18

Review 3.  Old and New Challenges in Uveitis Associated with Behçet's Disease.

Authors:  Julie Gueudry; Mathilde Leclercq; David Saadoun; Bahram Bodaghi
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

4.  Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab.

Authors:  Anna Cardiakidis Myers; Fredrik Ghosh; Sten Andréasson; Vesna Ponjavic
Journal:  Curr Eye Res       Date:  2014-06-04       Impact factor: 2.424

5.  Ocular toxicity of intravitreal golimumab in a rabbit model

Authors:  Ceren Durmaz Engin; Serap Cilaker Miçili; Osman Yilmaz; Hüsnü Alper Bağriyanik; Bekir Uğur Ergür; Fatoş Önen; Ali Osman Saatci
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

6.  An experimental study to evaluate safety/toxicity of intravitreal natalizumab.

Authors:  Rohan Chawla; Madhu Nath; Laxmi Moksha; Tapas C Nag; Thirumurthy Velpandian
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

Review 7.  A review of ocular adverse events of biological anti-TNF drugs.

Authors:  Fernanda Nicolela Susanna; Carlos Pavesio
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-04-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.